Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery.
| Revenue (TTM) | $2.25B |
| Gross Profit (TTM) | $1.24B |
| EBITDA | $403.90M |
| Operating Margin | 10.10% |
| Return on Equity | -0.70% |
| Return on Assets | 1.75% |
| Revenue/Share (TTM) | $51.16 |
| Book Value | $68.55 |
| Price-to-Book | 1.82 |
| Price-to-Sales (TTM) | 2.29 |
| EV/Revenue | 3.429 |
| EV/EBITDA | 30.21 |
| Quarterly Earnings Growth (YoY) | -17.30% |
| Quarterly Revenue Growth (YoY) | 28.90% |
| Shares Outstanding | $42.37M |
| Float | $42.21M |
| % Insiders | 0.63% |
| % Institutions | 114.57% |
Volatility is currently contracting
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
TFX, CNC, ENS, ROCK and FAF stand out among five low P/B stocks offering attractive value and promising growth prospects.
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portf.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a.
TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TFX and any ticker you trade — then tracks every position and per-strategy win rate.
